Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Houston, TX
October 27, 2009
Outline
Introduction to FDA and DPQR Drug product shelf life & expiration date Shelf-Life Extension Program (SLEP) Repackaged products
CDER
Drugs
CBER
Biologics
CDRH
CVM
CFSAN
Food Cosmetics
NCTR
Devices Veterinary
Combination products
Field Laboratories Office of Biotech Laboratories Office of Testing and Research Laboratories
3
Research in DPQR
DS
Analytical
Methods Excipients Formulation variables Process variables Mechanistic evaluations Optimization & ANN procedures
DP
Characterization Stability
Nanoparticles
Liposomes SR/MR TDDS Nasal Pulmonary Fast disintegration Solid dispersion
Physical
Chemical
Levothyroxine Sodium
I HO I ONa H I O I NH2 x H2O O
Peak area
175
75
-25 0
Tyr
10 Time (min)
Theo
MIT
15
T4
20
Analyze data for each attribute as a function of time against proposed acceptance criteria Determine if the proposed shelf life can be supported by available data
9
105
% Label Claim
100
95
90
85 0 1 2 3 4 5
10
Time (years)
11
Gabapentin
Example of a drug product impurity
H2N COOH
HN C=O
Lactam impurity Gabapentin J. Pharm and Biomed. Analysis, 2008, 46, pp. 181-186. * Laboratory efforts: Understand all the variables and their interactions that enhance the impurity level. DOE experiments to obtain a design space of a unit operation. Drying and granulation process monitored by Near IR and chemical imaging.
12
Potency (% claim)
95 90 85
PVP-W PVP-A xPVP-A HPC-A Polx-A
80 75 70 0 2 4 6 8 Time (weeks)
10
12
14
13
2.0 1.6
6 8 Time (weeks)
10
12
14
14
HPC-W Polx-W
6 8 Time (weeks)
10
12
14
15
Samples
FDA Field Lab Testing
16
Group 1A: Products with No Failures ( 10 lots tested) Drug Product Amoxicllin Sodium Ciprofloxacin Diphenhydramine HCl Doxycycline Hyclate Doxycycline Hyclate Halothane Mannitol Morphine Sulfate Naloxone HCl Oxacillin Sodium Potassium Iodide Sodium Bicarbonate Sodium Chloride Sodium Nitrite Sodium Thiosulfate Dosage Form Tablets Tablets Syringe-Needle a Capsules b Powder b Liquid Injection-Solution Syringe-Needle c Injection-Solution Powder Tablets d Injection-Solution Irrigation e Injection-Solution Injection-Solution Tested 21 242 12 13 31 12 10 13 10 13 12 37 16 10 14 Mean 23 55 76 50 27 67 66 89 77 56 69 55 72 89 131 17
Cefoperazone Sodium Cephapirin Sodium Cimetidine HCl Dextrose (5%) Flurazepam HCl Morphine Sulfate Ophthalmic Irrigating Pancuronium Bromide Ringers, Lactated and Dextrose Sodium Chloride Sodium Polystyrene Sulfonate Sulfadiazine Silver Tetracycline HCl Thiopental Sodium
Powder Powder Injection-Solution c Injection-Solution Capsules Autoinjector d Solution Injection-Solution Injection-Solution Injection-Solution e Powder Cream Capsules Powder
4 13 7 22 3 3 6 13 13 41 3 37 11 12
46 74 42 65 35 32 52 79 53 50 55 57 50 54
Assay Potency Assay Assay; Appearance i Appearance Degradant Low pH Assay (1) Assay k ; Assay, Appearance Assay; pH Water Content High pH & Assay Dissolution ; Degradant Low pH ; Appearance 18
SLEP Participants
CDC/Strategic National Stockpile (SNS) since 2004 Dept. of Veterans Affairs (VA) since 2005 Only Federal agencies that sign an MOA with DOD may participate in SLEP
19
SLEP Challenges
Protocols/Procedures References standards Specialized equipment Lab research when needed Record keeping Knowledge Management
20
5 4
Force (Kg)
1975 1999
Hardness (kp)
2004
3 2 1 0 0.0 0.5 1.0 1.5 2.0 Distance (mm) 2.5 3.0 3.5
4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 1975
F or c e
2004
21
Research Lessons Actual shelf life may be much longer than Learned
indicated by expiration date on the product original label. Shelf life varies greatly between lots. Continued testing and systematic evaluation is required to ensure product quality. Analyses of the successes and failures can help in applying this information to new product development.
22
Two repackaging firms say a draft FDA guidance should be revised to allow one year dating on open dose packages using Class B material. ('http://www.fdaweb.com/start.php?sa=v&aid=D51 00826&cate=&stid=4LnsBWacYRN0k') FDA Webview, Sept 12, 2005
24
Original packaging tablets Stored at 25C 60%RH for 4 Weeks Original packaging tablets Stored at 40C 75%RH for 4 Weeks
Repackaged tablets Stored at 25C 60%RH for 4 Weeks Repackaged tablets Stored at 40C 75%RH for 4 Weeks
26
Overall Conclusions
Drug product degrade by several different type of reactions It is important to monitor several product attributes in addition to the amount of main drug The stability of a product beyond expiration is not evaluated. Some product could be dangerous if used after expiration SLEP program is restricted to certain federal agencies at this time Repackaged metoprolol tartrate tablets Product integrity compromised at accelerated conditions. Repackaged Phenytoin Sodium Suspension Product uniformity, potency, and dissolution compromised at initial time point itself Repackaged Ranitidine HCl Syrup, Furosemide Tablets, and Gabapentin Capsules no stability issues in the conditions of experiment
27